News

Patent Office grants Alnylam new claims on its RNAi delivery method

Alnylam announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics conjugated with an N-acetylgalactosamine (GalNAc) ligand independent of length, sequence, or disease target," according to a statement. 

Titan Phase III trial for subdermal implant begins enrollment

A year after the FDA rejected Titan Pharmaceutical's Probuphine subdermal implant for the treatment of opioid dependence, the company is knocking on the approval door once again. It announced July 21 that the first patients have enrolled in its Phase III trial designed to address the FDA's questions.

Galena Biopharma to market anti-vomit oral soluble film to cancer patients

Galena Biopharma believes that its experienced oncology sales team will enable it to effectively market Zuplenz, the only oral soluble film for preventing vomiting following chemotherapy and radiotherapy, which it will soon offer thanks to a licensing agreement struck with MonoSol Rx, the developer of the product's delivery technology.

Phase II trial kicks off for sublingually delivered Parkinson's therapy

A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.

Plant genes could combat resistance to hemophilia drugs

A biochemist has designed a method for improving the treatment of hemophilia using a plant-based drug delivery system that combats resistance to standard clotting factors, which afflicts about one-fourth of those with the disease. 

Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer

Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.

Delivering breast cancer drug through the skin grants disease prevention

Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.

Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve

Boston Scientific's Ranger drug-coated balloon catheter was recently awarded a CE mark for its 25-mm Lotus Transcatheter Aortic Valve Implantation System.

UPenn researchers develop nanogel for mitigating lung inflammation

Researchers at the University of Pennsylvania said they have uncovered a delivery method to treat acute pulmonary inflammation, a condition that afflicts patients suffering from multiple blood transfusions, sepsis, lung surgery and acute lung trauma and has a mortality rate as high as 40%.

Nasal version of naloxone for opioid overdose gets on FDA's fast track

The first nasally administered naloxone-based therapy to treat emergency cases of opioid overdose from heroin or prescription painkillers received a Fast Track Designation from the FDA, product developer AntiOp said in a July 15 statement.

InSite plans 2015 FDA submission for inflammation eye drop with suspended delivery

InSite Vision, working off its eye drop platform with polymer-suspended drug delivery, is planning to submit an NDA in 2015 for its treatment for blepharitis, an eyelid inflammation disease for which there is currently no FDA-approved treatment.

Researchers develop new chemo that targets mitochondrial DNA

Researchers at the University of Georgia have developed a new formulation of the chemotherapy drug cisplatin that targets mitochondrial DNA, and is delivered via a polymeric nanoparticle 1,000 times smaller than the width of human hair.

Sanofi Pasteur taps CureVac for its RNA vaccine tech

Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.

Sorrento receives grant from NIH to study antibacterial drug delivery

The U.S. National Institutes of Health granted Sorrento Therapeutics $2.6 million to develop antibacterial immunotherapies.

MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery

A new contraceptive implant developed by Lexington, MA-based MicroCHIPS could give women remote-controlled access to their hormone administration, offering up to 16 years of specifically dosed delivery and thus more authority over their birth control regimens.

Vaginal ring achieves localized, sustained release of anti-HIV drugs

A novel intravaginal ring to prevent HIV showed promise in pig-tailed macaque monkeys, demonstrating the benefits of sustained and controlled topical drug delivery over oral intake. 

BioDelivery Sciences Phase III study of gel for diabetic neuropathy to commence

BioDelivery Sciences has completed enrollment of it Phase III study clonidine topical gel for the treatment of painful diabetic neuropathy (PDN).

Muscle cell-powered 'bio-bot' could carry drugs

Self-propelled drug delivery robots offer the type of precise targeting and maneuverability needed to make better treatments. And U.S. engineers have designed a type of robot that's powered by real muscle cells, offering controlled movement via electrical pulses, an innovation that could find its way into the drug delivery arena down the road.

Researchers aim to sneak antibiotics into bacteria via naturally occurring molecule

Researchers are attempting to develop methods of sneaking drugs past bacteria's external defense system by delivering therapies via molecules that bacteria secrete to find and obtain iron. 

BMS recalls injectable warfarin, oral formulation unaffected

Bristol-Meyers Squibb recalled six lots of 5 mg single-use vials of Coumadin for Injection due to the presence of particulate matter, but the FDA said the issue does not affect the more prevalent oral formulation of the popular blood thinner.